Latest Ligand Pharmaceuticals Inc (LGND) Headlines
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 5:15PM CST
Supplemental New Drug Application (sNDA) for Promacta to the FDA
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta(R) (eltrombopag) for Severe Aplastic Anaemia
Business Wire - Fri Feb 28, 8:57AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta(R) (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
Ligand to Present at the 26th Annual Roth Conference on March 11
Business Wire - Wed Feb 26, 8:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.
Insider Trading Alert - LCI, POWI And LGND Traded By Insiders
at The Street - Fri Feb 21, 10:30AM CST
Stocks with insider trader activity include LCI, POWI and LGND
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
Research and Markets: US Hospital Hematology and Flow Cytometry Market 2014
Business Wire - Thu Feb 13, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjkv69/us_hospital) has announced the addition of the "US Hospital Hematology and Flow Cytometry Market 2014" report to their offering.
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.27%
Comtex SmarTrend(R) - Wed Feb 12, 5:54PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $70.00 to a high of $76.77. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $71.92 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ligand Beats Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:42AM CST
Ligand Pharmaceuticals Inc. (LGND) reported fourth quarter 2013 (ending Dec 2013) adjusted earnings of 28 cents per share, beating the Zacks Consensus Estimate of 20 cents.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 11, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Stocks End Near Session Highs; Ligand, Regeneron Jump
at Investor's Business Daily - Tue Feb 11, 3:24PM CST
The major averages rose 1% Tuesday, closing just off session highs, after Fed Chairwoman Janet Yellen reassured markets the central bank will remain accommodative. The Dow Jones industrial average led the way, rising 1.2%. The S&P 500 added 1.1% and...
Why Ligand Pharmaceuticals Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 11, 2:56PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ligand Pharmaceuticals , a biotechnology...
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Feb 11, 7:30AM CST
--Conference Call Begins at 9:00 a.m. Eastern Time Today
Ligand to Receive $1 Million Kyprolis(R) Commercial Milestone Payment from Onyx Pharmaceuticals
Business Wire - Mon Feb 10, 3:15PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned $1 million commercial milestone payment from Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.). The milestone payment was triggered by the achievement of over $250 million of annual product sales of Kyprolis in 2013. Ligand will recognize the $1 million payment in the first quarter of 2014, consistent with the Company's revenue recognition policy. Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones.
Spectrum rises as FDA starts lymphoma drug review
AP - Thu Feb 06, 1:18PM CST
NEW YORK (AP) — Shares of Spectrum Pharmaceuticals rose Thursday after the company said the Food and Drug Administration will conduct a fast review of its lymphoma drug Beleodaq.
Bright Outlook at Ligand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 10:30AM CDT
Ligand provided a rosy outlook at the 2014 Roth Healthcare conference.
Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference
Business Wire - Tue Mar 11, 3:15PM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented today at the Roth Capital Conference in Dana Point, California, where it reviewed its business and financial highlights, its unique R&D model and selected un-partnered programs, and provided partnering case studies.
Ligand Pharmaceuticals' NDA for carbamazepine IV accepted for review by US FDA
M2 - Tue Mar 11, 7:19AM CDT
US-based biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) said on Monday that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational intravenous formulation of the anti-epileptic drug, carbamazepine.
Commit To Buy Ligand Pharmaceuticals At $65, Earn 22.6% Annualized Using Options
at The Street - Mon Mar 10, 10:45AM CDT
Investors considering a purchase of Ligand Pharmaceuticals Inc stock, but tentative about paying the going market price of $69.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting...
Captisol(R) Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV
Business Wire - Mon Mar 10, 9:12AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Captisol(R) licensee Lundbeck LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug carbamazepine. An action letter is anticipated before the end of 2014. Carbella(TM) (carbamazepine) Injection is the proposed U.S. trade name. With acceptance of the NDA filing, Ligand earns a $200,000 milestone payment.
Appointments, Earnings Results, Drug Applications, Conferences, and Approvals - Analyst Noteson Boston Scientific, Covidien, St. Jude Medical, Synageva BioPharma, and Ligand Pharmaceuticals
PR Newswire - Wed Mar 05, 3:00PM CST
Editor Note: For more information about this release, please scroll to bottom.
Glaxo/Ligand Look to Expand Promacta Label - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 5:15PM CST
Supplemental New Drug Application (sNDA) for Promacta to the FDA
Ligand Partner GlaxoSmithKline Submits U.S. Regulatory Application for Promacta(R) (eltrombopag) for Severe Aplastic Anaemia
Business Wire - Fri Feb 28, 8:57AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline plc (LSE:GSK) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Promacta(R) (eltrombopag) for the treatment of cytopenias (a reduction in blood cells) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).
Ligand to Present at the 26th Annual Roth Conference on March 11
Business Wire - Wed Feb 26, 8:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John Higgins, President and Chief Executive Officer and Matt Foehr, Chief Operating Officer and Executive Vice President of Ligand, will present at the 26th Annual Roth Conference on Tuesday, March 11, 2014 at 1:30 p.m. Pacific (4:30 p.m. Eastern Time). The conference takes place at The Ritz-Carlton in Dana Point, California.
Insider Trading Alert - LCI, POWI And LGND Traded By Insiders
at The Street - Fri Feb 21, 10:30AM CST
Stocks with insider trader activity include LCI, POWI and LGND
2 Health Care Partnerships Go Head-To-Head
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 14, 1:30PM CST
The health care space is full of collaborative arrangements, with many pharmaceutical companies in particular forming partnerships with peers to share the development costs (and risk) involved in developing new drugs and treatments. However,...
Research and Markets: US Hospital Hematology and Flow Cytometry Market 2014
Business Wire - Thu Feb 13, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjkv69/us_hospital) has announced the addition of the "US Hospital Hematology and Flow Cytometry Market 2014" report to their offering.
Ligand Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 4.27%
Comtex SmarTrend(R) - Wed Feb 12, 5:54PM CST
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $70.00 to a high of $76.77. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $71.92 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Ligand Beats Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:42AM CST
Ligand Pharmaceuticals Inc. (LGND) reported fourth quarter 2013 (ending Dec 2013) adjusted earnings of 28 cents per share, beating the Zacks Consensus Estimate of 20 cents.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 11, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Stocks End Near Session Highs; Ligand, Regeneron Jump
at Investor's Business Daily - Tue Feb 11, 3:24PM CST
The major averages rose 1% Tuesday, closing just off session highs, after Fed Chairwoman Janet Yellen reassured markets the central bank will remain accommodative. The Dow Jones industrial average led the way, rising 1.2%. The S&P 500 added 1.1% and...
Why Ligand Pharmaceuticals Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 11, 2:56PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ligand Pharmaceuticals , a biotechnology...
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Feb 11, 7:30AM CST
--Conference Call Begins at 9:00 a.m. Eastern Time Today
Ligand to Receive $1 Million Kyprolis(R) Commercial Milestone Payment from Onyx Pharmaceuticals
Business Wire - Mon Feb 10, 3:15PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has earned $1 million commercial milestone payment from Onyx Pharmaceuticals (a subsidiary of Amgen, Inc.). The milestone payment was triggered by the achievement of over $250 million of annual product sales of Kyprolis in 2013. Ligand will recognize the $1 million payment in the first quarter of 2014, consistent with the Company's revenue recognition policy. Ligand receives royalties for Kyprolis and is eligible to receive additional commercial and regulatory milestones.
Spectrum rises as FDA starts lymphoma drug review
AP - Thu Feb 06, 1:18PM CST
NEW YORK (AP) — Shares of Spectrum Pharmaceuticals rose Thursday after the company said the Food and Drug Administration will conduct a fast review of its lymphoma drug Beleodaq.
